On February 27, 2019 Turning Point Therapeutics, Inc., a clinical-stage precision oncology company developing novel drugs that address treatment resistance, reported that it will present preclinical data next month highlighting the potent activity of its kinase inhibitors against targeted oncogene drivers and their mutations (Press release, Turning Point Therapeutics, FEB 27, 2019, View Source [SID1234533755]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Four studies were accepted for presentation during poster sessions at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place March 29 to April 3 in Atlanta, including two presentations that further characterize lead clinical asset, repotrectinib, in tumor cells with clinically reported ROS1 and NTRK fusions and their corresponding mutations.
"The pervasive challenge of kinase mutations that lead to treatment resistance has limited the effectiveness of approved and investigational kinase inhibitors," said Athena Countouriotis, M.D., chief executive officer. "Our team has developed a pipeline of novel, small compact kinase inhibitors that have demonstrated early preclinical and clinical effectiveness against targeted gene fusions and their mutations. We are pleased to share several of our preclinical studies at AACR (Free AACR Whitepaper) as we continue to generate clinical evidence for our lead asset repotrectinib in our ongoing Phase 1/2 TRIDENT-1 study."
The preclinical antitumor activities of Turning Point’s TPX-0022, a MET/CSF1R/SRC inhibitor, will be presented for the first time in two poster presentations. TPX-0022 was designed to target not only MET-driven tumor cells by potent inhibition of MET/SRC signaling, but also modulate the tumor microenvironment by inhibition of CSF1R. This dual modulation has demonstrated significant tumor growth inhibition in preclinical models.
The four studies to be presented are:
Title: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
Session: Sunday Mar 31, 2019, 1:00 PM – 5:00 PM
Abstract Number: 4000
Title: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations
Session: Monday April 1, 2019, 8:00 AM – 12:00 PM
Abstract Number: 4832
Title: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling
Session: Monday April 1, 2019, 8:00 AM – 12:00 PM
Abstract Number: 3719
Title: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses
Session: Monday April 1, 2019, 8:00 AM – 12:00 PM
Abstract Number: 3749
Turning Point Therapeutics lead drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. A multi-cohort Phase 2 registrational study is planned for the second half of 2019. The company is also developing two multi-targeted kinase inhibitors — TPX-0046, a novel RET/SRC inhibitor, and TPX-0022, a novel MET/CSF1R/SRC inhibitor — and next-generation ALK inhibitors.
About Repotrectinib
Repotrectinib (TPX-0005) is a potent and orally bioavailable investigational small molecule kinase inhibitor of ROS1, TRKs and ALK. The clinical benefits of targeting ROS1, TRK, or ALK fusion kinases have been demonstrated with multiple kinase inhibitors already approved or in clinical studies. The successes of these therapies are often overshadowed by the development of acquired resistance. The acquired solvent front mutations including ROS1 G2032R, TRKA G595R and TRKC G623R, and ALK G1202R render common clinical resistance to the current ROS1, TRK, and ALK inhibitors.
Repotrectinib has demonstrated potency against wildtype and mutated ROS1, TRK and ALK kinases, especially the clinically significant solvent front mutations, gatekeeper mutations, and emerging compound mutations after multiple lines of treatment. Repotrectinib may provide a new opportunity to inhibit the abnormal signaling of ROS1, TRK or ALK in solid malignancies, and overcome multiple resistance mechanisms seen in resistant patients. Repotrectinib is currently being evaluated in a Phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements TRIDENT-1 study (www.clinicaltrial.gov number NCT03093116). Interested patients and physicians can also contact the TP Therapeutics Oncology Clinical Trial Hotline at 1-858-276-0005 or email [email protected].